Heart and Blood Diseases

All Conditions

Rare Diseases

Myocarditis

Cardiomyopathies

Heart Diseases

Acute Graft Versus Host Disease

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Immune Checkpoint Inhibitors

Abatacept

Antineoplastic Agents, Immunological

Immunosuppressive Agents

Immunologic Factors

Abatacept (10 mg/kg) will be administered IV after randomization, again at 24 hours after first study drug treatment, at 14 days after first study drug treatment and an optional 4th dose at 28 days.

Placebo will be administered at the same intervals.

Up to 4 study drug infusions at 10 mg/kg, IV

Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC

Abatacept plus

Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC

Placebo

Hannah K Gilman, MS

Kiranbir Josan, MD

Eric Yang, MD

Hayder Hashim

Mohammed v

Mohammed Alomar

Jeanne DeCara

Ryan Daly

Ryan Daly, MD

Charles Porter

Charles Porter, MD

Amit Arbune

Amit Arbune, MD

Maxwell Afari

Maxwell Afari, MD

Joban Vaishnav

Daniel Zlotoff, MD, PhD

Kerry Reynolds, MD

Abul Aritizia, MD

Aarti Asnani, MD

Omar Siddiqi

Omar Siddiqi, MD

Anju Nohria, MD

Salim Hayek, MD

Joerg Herrmann

Joerg Herrmann, MD

Amna Zafar

Jayant Raikhelkar

Dipti Gupta, MD

Brian Jensen, MD

Rohit Moudgil

Nicholas Trask

Deborah Sundlof

Michael Fradley

Valentyna Ivanova

Ivanova Ivanova, MD

Saketh Nadimpalli

Vlad Zaha, MD

Nicolas Palaskas

Nicolas Palaskas, MD

Anees Daud, MD

Brijesh Patel

Brijesh Patel, MD

Manmeet Singh

Margot Davis

Margot Davis, MD

Darryl Leong

Darryl Leong, MD

The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.

This investigator-initiated randomized trial is being conducted to test whether abatacept, as compared to placebo, is associated with a reduction in MACE among participants who develop myocarditis after treatment with an ICI. Immune checkpoint inhibitors leverage the immune system to treat a wide variety of cancers. Myocarditis is an uncommon immune related adverse event (irAE) secondary to treatment with an ICI. The guideline recommended treatment for ICI myocarditis is cessation of the ICI and administration of corticosteroids. However, despite administration of corticosteroids, the rate of MACE with ICI myocarditis is high. Data from multiple independent international cohorts have shown that the rate of MACE with ICI myocarditis despite administration of corticosteroids ranges from 25-50%.For comparison, the rate of MACE with myocarditis unrelated to an ICI is \<5%.

Abatacept is a selective co-stimulation modulator that inhibits T cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking its interaction with CD28. This interaction provides a costimulatory signal necessary for full activation of T lymphocytes. In animal studies of ICI myocarditis, the administration of abatacept led to a reduction in cardiac immune activation and an increase in survival. In retrospective unpublished clinical data, the administration of abatacept to participants with ICI myocarditis on corticosteroids was associated with a reduction in risk of MACE. There are no prospective studies testing whether abatacept is effective among participants with ICI myocarditis. Therefore, the primary aim of this trial is to test in a randomized double-blind placebo-controlled study whether abatacept, administered concurrently with corticosteroids, is associated with a reduction in MACE among participants with recently diagnosed ICI myocarditis

Abatacept in Immune Checkpoint Inhibitor Myocarditis

AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis

The rates of a composite of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrhythmias, significant bradyarrhythmias, or incident heart failure.

The rates of the following between groups: cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrhythmias, significant bradyarrhythmias, or incident heart failure

The worst score on a 7-point ordinal myocarditis severity scale during the 6 month period from first study treatment. The 7-point ordinal myocarditis severity scale is as follows with more severe outcomes ranked with a higher number:

1. - No component of the primary endpoint;
2. - Incident heart failure;
3. - Significant bradyarrhythmia;
4. - Significant ventricular tachyarrhythmias;
5. - Cardiogenic shock;
6. - Sudden cardiac arrest;
7. - Cardiovascular death;

The proportion of participants in each group with a \>50% increase in serum troponin value at any time during the incident hospitalization and following administration of study drug.

The rates of a composite of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrhythmias, significant bradyarrhythmias, or incident heart failure plus the proportion of participants in each group with a \>50% increase in serum troponin value at any time during the incident hospitalization and following administration of study drug.

Clinical status at visit 6 (day 90) on an ordinal scale with highest being the worst:

1. - Alive and off corticosteroids for myocarditis;
2. - Alive and on corticosteroids (provide dose) for myocarditis;
3. - Alive and on cellcept (provide dose) for myocarditis;
4. - Alive and on both corticosteroids (provide dose) and cellcept (provide dose) for myocarditis
5. - Dead (cancer, cardiovascular or other).

Clinical status at visit 7 (6 months) with the highest being the worst:

1. - Alive and off corticosteroids for myocarditis;
2. - Alive and on corticosteroids (provide dose) for myocarditis;
3. - Alive and on cellcept (provide dose) for myocarditis;
4. - Alive and on both corticosteroids (provide dose) and cellcept (provide dose) for myocarditis
5. - Dead (cancer, cardiovascular or other).

The proportion of patients in each group with a fatal and non-fatal DVT and PE will be compared.

Rates of other immune-related adverse events between the two groups will be compared.

Bristol-Myers Squibb

Massachusetts General Hospital

Director, Cardio-Oncology Program

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Abatacept in Immune Checkpoint Inhibitor Myocarditis	NCT05335928	Myocarditis Acu... Cancer	Abatacept plus Placebo	18 Years -	Massachusetts General Hospital
Abatacept in Immune Checkpoint Inhibitor Myocarditis	NCT05335928	Myocarditis Acu... Cancer	Abatacept plus Placebo	18 Years -	Massachusetts General Hospital

Spots Global Cancer Trial Database for immune related adverse events